Noribogaine effects on wakefulness and sleep
Juan Pedro Castro-Nin, Diego Serantes, Paola Rodrı́guez, Bruno González, Ignacio Carrera, Pablo Torterolo, Joaquín González
bioRxiv (Cold Spring Harbor Laboratory) July 28, 2023 preprint DOI: 10.1101/2023.07.26.550725 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study |
|---|---|
| Population | Rats |
| Intervention | noribogaine |
| Topics | Ibogaine |
| Keywords | Wakefulness Sleep system call Slow-wave sleep Antidepressant Pharmacology Hippocampus Electroencephalography |
| Citations | 1 |
| Key findings | Noribogaine promotes wakefulness, reduces slow-wave sleep, and blocks REM sleep in rats, similar to ibogaine. |
Abstract
Abstract Ibogaine is a potent atypical psychedelic that has gained considerable attention due to its antiaddictive and antidepressant properties in preclinical and clinical studies. Previous research from our group showed that ibogaine suppresses sleep and produces an altered wakefulness state which resembles natural REM sleep. However, after systemic administration, ibogaine is rapidly metabolized to noribogaine, which also shows antiaddictive effects and a distinct pharmacological profile, making this drug a promising therapeutic candidate. Therefore, whether the sleep/wake alterations depend on ibogaine or its principal metabolite noribogaine remains unknown. To answer this question, we conducted polysomnographic recordings in rats following the administration of pure noribogaine. Our results show that noribogaine promotes wakefulness while reducing slow-wave sleep and blocking REM sleep. Thus, like ibogaine, noribogaine significantly alters the sleep-wake architecture, highlighting the possible role of serotonin reuptake inhibition as a likely candidate underlying the wake-promoting and REM sleep-suppressing effects.
Comparable studies
Other preclinical and animal studies on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine TE671/RD cells (human muscle-type nAChR) and SH-SY5Y neuroblastoma cells (human... | 1999 | In vitro study | |
| Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Ibogaine- or harmaline-treated rats | 1993 | Experimental animal study | |
| Effects and aftereffects of ibogaine on morphine self-administration in rats. Rats | 1991 | Preclinical experimental study | |
| Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Rats | 1994 | Experimental study | |
| Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption Rats | 2005 | Experimental study |
Citations in the library
Cites 31
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021
- Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Science February 16, 2023
- Psychedelics promote plasticity by directly binding to BDNF receptor TrkB Nature Neuroscience June 1, 2023
and 26 more in the library